Worldwide Clinical Trials

OCTOBER 14, 2024

Fortunately, advances in clinical research are providing hope for better treatments and outcomes. With the support of global networks like ours at Worldwide Clinical Trials (Worldwide), autoimmune and bone health research is accelerating, providing new solutions to patients around the world.

Research 147

Research Clinical Trials Clinical Trials Immune Response 147

pharmaphorum

MAY 19, 2022

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV vaccine in Africa, where the burden of the virus is still being keenly felt. One candidate – mRNA-1644 – has already shown its potential in an earlier phase 1 trial (IAVI G001) run in the US.

Vaccination 145

Vaccination Vaccine Trials Immune Response 145

Worldwide Clinical Trials

OCTOBER 14, 2024

Fortunately, advances in clinical research are providing hope for better treatments and outcomes. With the support of global networks like ours at Worldwide Clinical Trials (Worldwide), autoimmune and bone health research is accelerating, providing new solutions to patients around the world.

Research 130

Research Clinical Trials Clinical Trials Immune Response 130

Rethinking Clinical Trials

APRIL 18, 2023

There are many hypothesized causes that may co-exist in the same patient, such as persistent virus or antigens, reactivation of other viruses, uncontrolled immune responses, damage to a wide range of organs and tissues, and injury to blood vessels and abnormal blood clotting. The first trial will begin enrolling in July 2023.

Clinical Trials 169

Clinical Trials Clinical Trials Trials Immune Response 169

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. This marks the second time one of Janssen’s HIV vaccines failed after another showed disappointing results in the Phase IIb Imbokodo trial in August 2021.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

World of DTC Marketing

DECEMBER 29, 2020

Once introduced into the human body, the protein-making machinery uses this genetic material in our cells to churn out the coronavirus “spike protein,” triggering an immune response. Another consideration is that while in traditional vaccine development, clinical trials are carried out in sequence. Then there are the finances.

Vaccination 307

Vaccination Vaccine Development Clinical Trials 307

pharmaphorum

FEBRUARY 25, 2021

Maryland, US-based company Altimmune is among the biotechs and research labs trying to find more convenient alternatives and believes a nasal vaccine spray that is stable at room temperature could be the answer. A nasal delivery method will also produce an immune response at the point where the virus enters the body.

Vaccination 111

Vaccination Vaccine Immune Response Trials 111

XTalks

OCTOBER 24, 2024

Trends in Psoriasis Research: Biologics, Biosimilars and New Therapies Recent innovations in biologics and biosimilars have transformed psoriasis care. In August 2024, Artax Biopharma completed patient recruitment for its Phase IIa trial of AX-158, exploring a new immune-modulating therapy for psoriasis.

Research 105

Research Dermatology Clinical Trials Clinical Trials 105

Pharmaceutical Technology

AUGUST 24, 2022

Patients provide blood samples for clinical trial sponsors to develop and deliver these emerging immunotherapies. Flow cytometry (FCM) is the primary method scientists use to monitor immune responses in clinical trials, primarily because of its power, speed, and ability to provide a comprehensive view of a disease’s macro-environment.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

World of DTC Marketing

APRIL 11, 2021

Further scientific research into the virus and recognition that it was not like influenza A, a flu virus known to cause bronchitis, would transpire over the next 30 years. . If your body develops an immune response—the goal of vaccination—there is a possibility you may test positive on some antibody tests.

Vaccination 303

Vaccination Vaccine Clinical Trials Clinical Trials 303

Pharmaceutical Technology

SEPTEMBER 14, 2022

Successful TIL therapy depends on the infusion product containing tumour-reactive T cells that, on infusion, generate an anti-tumour immune response that causes disease regression. The use of engineered immune cytokines that selectively induce the expansion of TILs is being investigated as an alternative to IL-2 stimulation.

Immune Response 246

Immune Response In-Vivo Production Manufacturing 246

pharmaphorum

NOVEMBER 26, 2020

AstraZeneca may have tried a positive spin on the trial mistake that led to the accidental discovery of the low dose COVID-19 vaccine regime with the highest efficacy– but the revelation has drawn a mixed response from commentators.

Vaccination 98

Vaccination Vaccine Trials Immune Response 98

XTalks

MAY 4, 2023

However, there are ongoing clinical trials for celiac disease to investigate potential new treatments. Some of the approaches being studied include: Enzyme therapy: Researchers are testing enzymes that may help break down gluten in the digestive system, reducing the risk of immune system activation and damage to the small intestine.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Immune Response 98

BioSpace

NOVEMBER 7, 2022

Researchers from the University of Washington have developed an investigational vaccine that can safely elicit an immune response against the HER2 protein, a key marker in breast cancer.

Immune Response 87

Immune Response Vaccination Vaccine Protein 87

XTalks

NOVEMBER 15, 2024

Syros Pharmaceuticals announced that its cancer drug tamibarotene failed to meet its primary endpoint in the SELECT-MDS-1 Phase III trial. The placebo-controlled SELECT-MDS-1 trial involved 190 patients with complete response rate (CRR) being the study’s primary endpoint. percent and 18.8

Trials 98

Trials HR Immune Response FDA Approval 98

Medical Xpress

JANUARY 30, 2023

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

Vaccination 106

Vaccination Vaccine Immune Response Allergies 106

Pharmaceutical Technology

OCTOBER 6, 2022

BioLink Life Sciences has received a contract worth $750,000 from the US Biomedical Advanced Research and Development Authority (BARDA) to develop Ramatroban for treating Covid-19 pneumonia patients in the hospital setting. Ramatroban will be analysed in a placebo-controlled, randomised Phase II/III RAMBAN-1 clinical trial.

Development 162

Development Life Science Immune Response Trials 162

pharmaphorum

SEPTEMBER 24, 2020

The UK could be the first country to carry out a COVID-19 “challenge trial” where healthy volunteers are deliberately infected with coronavirus to test vaccines, according to press reports. “These discussions are part of our work to research ways of treating, limiting and hopefully preventing the virus so we can end the pandemic sooner.”

Vaccination 98

Vaccination Vaccine Trials Immune Response 98

Worldwide Clinical Trials

MARCH 12, 2024

There are several additional tumor markers illustrated below: Circulating Tumor Cells Are Hard to Detect but Reduce Patient Burden Tumor cells sometimes break away from the tumor and circulate in the bloodstream, allowing researchers to measure them as circulating tumor cells (CTCs).

Clinical Trials 182

Clinical Trials Clinical Trials Immune Response Trials 182

pharmaphorum

DECEMBER 17, 2020

Trials of a fifth COVID-19 vaccine have begun in the UK, as IT issues threaten to delay the roll-out of the shot from Pfizer/BioNTech. France’s Valneva begun the phase 1/2 clinical study of the inactivated vaccine candidate VLA2001 in sites across the UK, supported by the National Institute for Health Research (NIHR).

Vaccination 105

Vaccination Vaccine Trials Immune Response 105

Scienmag

JUNE 27, 2021

The first human trial has shown no obvious side effects and a good immune response. Researchers based […]. Hiroshi Kiyono, CC BY 4.0 A new vaccine to protect against deadly cholera has been made by grinding up genetically modified grains of rice.

Vaccination 72

Vaccination Vaccine Immune Response Trials 72

pharmaphorum

OCTOBER 11, 2022

An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong immune response to the virus.

Vaccination 116

Vaccination Vaccine Immune Response Development 116

Worldwide Clinical Trials

JUNE 21, 2024

The 2024 ASCO Annual Meeting from the American Society of Clinical Oncology is a fantastic platform for clinical researchers to discuss the latest advancements and challenges in oncology research. Microenvironment Management : Optimizing the tumor microenvironment to enhance TIL efficacy remains a critical focus of research efforts.

Antibody 162

Antibody Clinical Trials Clinical Trials In-Vitro 162

pharmaphorum

JANUARY 6, 2023

The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. The post UK partners with BioNTech on clinical trials of mRNA cancer therapies appeared first on.

Clinical Trials 111

Clinical Trials Clinical Trials Trials Vaccination 111

pharmaphorum

NOVEMBER 25, 2021

The first patients are now being treated as part of a first-in-human trial of a vaccine, administered as a nasal spray, that aims to slow down the progression of Alzheimer’s disease (AD). Meanwhile researchers in Japan are also running preclinical studies of an intranasal tau vaccine.

Vaccination 98

Vaccination Vaccine Trials Immune Response 98

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. COVID-19 Clinical Trials.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

XTalks

DECEMBER 3, 2024

Building on this history of success, Novocure recently revealed promising Phase III results from the PANOVA-3 clinical trial, marking a significant milestone in pancreatic cancer treatment. Novocure’s broader pipeline underscores the versatility of TTFields therapy.

Trials 105

Trials Immune Response Clinical Trials Clinical Trials 105

XTalks

AUGUST 13, 2020

and BioNTech’s lead vaccine candidate in a Phase III trial being conducted at sites in California and Oregon. The company announced that it commenced the Phase III clinical trial to evaluate the investigational COVID-19 vaccine this week. Related: Pfizer and BioNTech’s COVID-19 Vaccine Shows Positive Early Trial Results.

Vaccination 89

Vaccination Vaccine Trials Clinical Trials 89

pharmaphorum

SEPTEMBER 30, 2020

This first data comes from a descriptive analysis from the seamless phase 1/2/3 trial that Regeneron hopes will hurry the medicine dubbed REGN-COV2 to market. The ongoing double-blind trial measures the effect of adding REGN-COV2 to usual standard of care, compared with usual standard of care. There were no deaths in the trial.

Antibody 135

Antibody Immune Response Trials Protein 135

Pharmaceutical Technology

MAY 19, 2023

OncoResponse has secured a $13m grant from the Cancer Prevention and Research Institute of Texas (CPRIT) and raised an additional $14m in funding from investors for advancing OR502 to investigational new drug (IND) and clinical trials. It is planned to enter clinical studies this year.

Immune Response 130

Immune Response Clinical Trials Clinical Trials Antibody 130

XTalks

OCTOBER 12, 2021

The experimental arthritis vaccine was developed by researchers at the University of Toledo (UToledo) and is a major breakthrough for rheumatoid arthritis and other autoimmune diseases as well. The vaccine was tested in rats and showed strong, immediate and long-lasting immune responses to confer protection against the disease.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

pharmaphorum

JUNE 29, 2021

Giving one dose each of AstraZeneca and Pfizer COVID-19 vaccines provides good protection against the SARS-CoV-2 virus, but may be associated with more adverse reactions, according to new clinical trial data. Third AZ dose generates strong variant response.

Immune Response 128

Immune Response Vaccination Vaccine Antibody 128

pharmaphorum

DECEMBER 11, 2020

Interim results from a phase 1/2 clinical trial show the immune response from Sanofi/GSK’s vaccine produced a lower immune response in older adults. While antibody levels were comparable to those seen in recovering COVID-19 patients in adults aged 18-49, the response was lower in older adults.

Immune Response 72

Immune Response Trials Vaccination Vaccine 72

XTalks

NOVEMBER 5, 2024

Proceeds from the IPO will fund preclinical and clinical development for Polyrizon’s innovative hydrogel product candidates, supporting further research and development (R&D). Initial testing is planned for late 2024 through early 2026, with further preclinical and Phase I trials depending on additional funding.

Drug Delivery 111

Drug Delivery Drugs Immune Response Allergies 111

Pharmaceutical Technology

MAY 10, 2023

XinThera’s therapy targeting MK2 is expected to enter clinical trials later in 2023. The acquisition will give Gilead Sciences access to XinThera’s portfolio of two small molecule inhibitor programmes, one of which targets PARP1 to treat cancer and the other of which targets MK2 for inflammatory diseases.

Immune Response 130

Immune Response DNA Clinical Trials Clinical Trials 130

pharmaphorum

NOVEMBER 25, 2022

While the shot is still in preclinical development, if it works in human trials it could raise the prospect of eventually sidestepping the annual scramble to guess the most likely strains to be circulating in the following flu season, and protect against future flu pandemics.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

STAT News

DECEMBER 23, 2022

In a clinical trial, 60% of patients with follicular lymphoma treated with Lunsumio achieved a complete response. The most common side effect was an overactive immune response called cytokine release syndrome, reported by 39% of patients. Continue to STAT+ to read the full story…

FDA Approval 98

FDA Approval Immune Response Drugs Research 98